Abstract Session 4

Co-Chair(s)

• 

  Steven P. Treon, MD, PhD, FACP, FRCP (he/him/his)

  Professor of Medicine, Harvard Medical School
  Dana-Farber Cancer Institute, Bing Center for Waldenstroms macroglobulinemia
  BOSTON, Massachusetts, United States
• 

  Andrew Spencer, MBBS FRACP, FRCPA, DM

  Professor
  Alfred Health-Monash University
  Melbourne, Victoria, Australia

Presentations:

• 10:00 AM – 10:12 AM East Coast USA Time

  OA – 05: Assessing the Effect of Previous Antibiotic Usage on Bispecific Monoclonal Antibody Therapy in Multiple Myeloma Patients
  

  Speaker: Roberto Garcia-Vicente, MSc (he/him/his) – Department of Translational Hematology, Research Institute Hospital 12 de Octubre (i+12), Hematological Malignancies Clinical Research Unit H120-CNIO, CIBERONC, Madrid, Spain
• 10:12 AM – 10:24 AM East Coast USA Time

  OA – 11: Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel (Cilta-cel) for Relapsed/Refractory Multiple Myeloma (RRMM): Real World Experience With Updated Follow-up
  

  Speaker: Surbhi Sidana, surbhi.sidana@stanford.edu – Stanford University
• 10:24 AM – 10:36 AM East Coast USA Time

  OA – 16: Long-term evaluation of minimal residual disease dynamics in Multiple Myeloma patients achieving complete response after first line treatment
  

  Speaker: Ioannis V. Kostopoulos, MSc, PhD (he/him/his) – Flow Cytometry Unit, Department of Biology, School of Sciences, National and Kapodistrian University of Athens, Athens, Greece
• 10:36 AM – 10:48 AM East Coast USA Time

  OA – 17: Liquid chromatography mass spectrometry (LC-MS) for identification of exceptional responders in newly diagnosed multiple myeloma (NDMM).
  

  Speaker: Tadeusz Kubicki, MD, PhD – University of Chicago
• 10:48 AM – 11:00 AM East Coast USA Time

  OA – 18: Association of Cardiac biomarkers and Adverse Events with a Carfilzomib-containing Quadruplet in High-risk Newly Diagnosed Multiple Myeloma Patients: Correlative Program of the GMMG-CONCEPT Trial
  

  Speaker: Lisa B. Leypoldt, MD (she/her/hers) – University Medical Center Hamburg-Eppendorf, Germany / Dana-Farber Cancer Institute, Boston, MA, USA